$-1.62 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO)

July 14, 2018 - By Darrel Chase

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.72 in 2018 Q1. Its up 0.50, from 1.22 in 2017Q4. It improved, as 13 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.93 million shares or 15.82% more from 45.70 million shares in 2017Q4 were reported.
Massachusetts-based Fernwood Investment Mngmt Limited Liability Corporation has invested 1.15% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Schwab Charles Inv Management reported 151,812 shares. Arrowmark Colorado Limited Liability holds 571,914 shares. Cap Interest Inc Ca has 0.19% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 16,200 shares. Hbk Invests Limited Partnership reported 6,764 shares or 0.01% of all its holdings. Tarbox Family Office reported 16 shares. Profund Advisors Limited Liability holds 0.05% or 15,875 shares in its portfolio. Fifth Third Bancorp invested in 155 shares. Asset Mgmt One invested in 0% or 10,863 shares. Verition Fund Limited Liability Co holds 0.05% or 8,228 shares. Goldman Sachs invested 0.02% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Rhumbline Advisers invested in 0.01% or 50,151 shares. Capital World owns 420,000 shares. 78,000 were accumulated by California Employees Retirement Sys. Capital Invsts has 0.27% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Since January 16, 2018, it had 1 insider purchase, and 32 selling transactions for $31.33 million activity. Hoerter Steven L. sold $175,808 worth of stock or 2,050 shares. On Thursday, February 1 Bowden Christopher sold $157,500 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,000 shares. Foster-Cheek Kaye I sold $841,926 worth of stock. Alenson Carman sold $23,104 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, July 9. 15,177 shares were sold by Biller Scott, worth $1.37 million. Shares for $16,688 were bought by Scadden David on Friday, March 16.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.62 EPS on August, 14.They anticipate $0.16 EPS change or 8.99 % from last quarter’s $-1.78 EPS. After having $-1.63 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -0.61 % EPS growth. The stock decreased 0.09% or $0.08 during the last trading session, reaching $90.4. About 158,829 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 88.28% since July 14, 2017 and is uptrending. It has outperformed by 75.71% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 7 analysts covering Agios Pharma (NASDAQ:AGIO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Agios Pharma had 8 analyst reports since February 14, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, February 15 by JP Morgan. The rating was initiated by Piper Jaffray with “Buy” on Wednesday, May 30. The company was initiated on Monday, June 18 by Oppenheimer. Credit Suisse maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Thursday, February 15. Credit Suisse has “Buy” rating and $80.0 target. As per Wednesday, April 11, the company rating was maintained by Credit Suisse. RBC Capital Markets maintained the shares of AGIO in report on Wednesday, February 14 with “Buy” rating.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.21 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and …” on June 26, 2018, also Nasdaq.com with their article: “Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals …” published on June 29, 2018, Nasdaq.com published: “Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency …” on June 18, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018 as well as Seekingalpha.com‘s news article titled: “Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal” with publication date: July 01, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.